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Abstract 
We investigate if rTMS has a therapeutic role in the treatment of dysphagia in 
patients with PD. 
Material and methods: 33 patients with PD and dysphagia were randomly 
classiﬁed with ratio 1:2 to receive sham or real rTMS (2000 pulses; 20 Hz; 90% 
RMT; 10 trains of 10s with 25s between each train) over the hand area of each 
motor cortex (5 min between hemispheres) for 10 days (5 days /week) followed 
by 5 booster sessions every month for 3 months.  Assessments included the 
Unified Parkinson’s Disease Rating Scale part III (UPDRS), Instrumental activity 
of Daily Living (IADL), and Arabic-dysphagia Handicap Index (A-DHI) before, after 
the last session, and 3 months later. Video-fluoroscopy measures of pharyngeal 
transit time (PTT) and time to maximal hyoid elevation (H1-H2) were taken before 
and after the treatment sessions. 
Results: There were no significant differences between groups. There was a 
significant improvement on all rating scales (ANOVA) after real rTMS with a 
significant time X group interaction. In particular there was a significant and long-
lasting (3 months) effect of time on all sub-items of the A-DHI (functional: P = 
0.0001; physical: P = 0.0001; emotional: P = 0.02) but not in the sham group. This 
was associated with significant improvement in H1-H2 (P = 0.03) and PTT (P = 
0.01) during solid swallows in the real rTMS but not the sham group.  
 
Conclusion: Real rTMS improves dysphagia in Parkinson’s disease as 
documented by A-DHI scores and by video-fluoroscopy. 
 
 
 
 
 
Introduction: 
Swallowing dysfunction is common in idiopathic Parkinson’s disease (PD), being 
symptomatic in up to 54.5% of patients especially in patients with predominantly 
akinetic rigidity [1] but seen in more than 90% using video-fluoroscopy [2-4]. It is 
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usually considered multifactorial with abnormalities documented in all phases of 
swallowing [3]. The underlying neurogenic mechanisms of swallowing dysfunction 
in PD are not well established although involvement of non-dopaminergic 
mechanisms has been suggested [5]. Indeed, even though levodopa treatment 
improves limb symptoms in PD [6] deglutitive dysfunction may fail to respond [7, 
5, 8], and may even occasionally deteriorate [9]. 
Current dysphagia management in PD patients is unsatisfactory. A number of 
approaches including dietary modification and swallowing maneuvers [10], 
dopaminergic and anticholinergic pharmacotherapy [11], expiratory muscle 
strengthening [12], video based biofeedback therapy [13], cricopharyngeal 
myotomy [14] and cricopharyngeus  botulinum toxin injection [15] have all been 
utilized with variable outcomes. 
 
More recently there have been a number of trials testing possible 
neuromodulatory techniques in PD patients with dysphagia.  One of these studies 
recruited 90 patients with PD and applied surface electrical stimulation over the 
submental region. At the end of the study there was significant improvement in 
the treated groups [16]. Dysphagia in other groups of patients has been treated 
with non-invasive brain stimulation (NIBS) techniques such as transcranial 
magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). A 
meta-analysis found that rTMS has a positive effect on dysphagia after stroke 
although the best frequency (low v high frequency) and site (affected, unaffected 
or bilateral hemispheres) has yet to be resolved [17-20]. However, there have 
been no studies of the effects of brain stimulation methods for dysphagia in 
patients with Parkinson’s disease. 
Given that rTMS has been shown to have beneficial effects on limb motor control 
in PD [21], we decided to conduct a trial to test its effectiveness on dysphagia. 
Given the proximity of the hand area of M1 (5 cm lateral to Cz and 1 cm anterior 
to Cz) to the esophageal motor area (6.6cm lateral to Cz and 3.0 anterior to Cz) 
[19], we hypothesized that we might achieve beneficial effects on both dysphagic 
and limb symptoms. 
Patients and Methodology:  
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Patients: 
90 PD patients with dysphagia using UK brain bank criteria for PD [22] were 
recruited from the outpatient clinic in Assiut University during the period from May 
2016- Jan 2018. Each patient was aged between 50-75 years and all fulfilled the 
UK brain bank criteria for PD. Patients were excluded if they had a history of 
repeated head injury, cerebrovascular strokes, encephalitis, oculogyric crisis, 
supranuclear  gaze palsy, drug intake as antipsychotics or MPTP exposure, 
severe dementia, (MMSE < 23) [23], severe depression (HAM-D) [24], severe 
dysautonomia, cerebellar signs, Babiniski sign, strictly unilateral features after 3 
years, hydrocephalus or intracranial lesion on neuroimaging. To allow delivery of 
rTMS patients were also excluded if they had intracranial metallic devices or with 
pacemakers or any other device. Patients who were unable to give informed 
consent were also excluded. Treatment was maintained constant throughout the 
trial with no change in dosage. All received levodopa (Sinemet 250/25; ½ tablet 
three times per day) and anticholinergic (cogenitol ½ tablet three times per day).  
The sample size was calculated using G power software based on the following 
assumptions: proportion of expected outcome in the intervention group=30% 
(according the previous study), proportion of the expected outcome in the placebo 
group=1%, alpha level=0.05, power=0.80 with allocation ratio N2/N1=1, using a 
one tailed test. 
Methods: 
All cases were assessed with modified Hoen and Yahr staging [25], Unified 
Parkinson's Disease Rating Scale (UPDRS) part III [26], instrumental daily living 
activity [27], Self-Assessment scale [28], Swallowing Disturbance Questionnaire 
(SDQ) for dysphagia for diagnosis of dysphagia [29], and Dysphagia Handicap 
Index (DHI) [30]. Video-fluoroscopy examination while patients were on levodopa 
therapy was performed for 9 patients in the real rTMS group and 6 from the sham 
group.  
The Swallowing Disturbance Questionnaire consists of five questions related to 
the oral phase of swallowing and 10 questions related to the pharyngeal phase. 
Fourteen questions were rated on a four-point (0–3) scale (0 for no disability and 
3 for  severe disability) and one was a “yes/no” question (yes was scored 2.5 and 
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no was scored 0.5). A score on the swallowing disturbance questionnaire (SDQ) 
of more than or equal to 11 indicates dysphagia. 
 A-DHI is a patient-administered, 25 item questionnaire, in which the patient can 
assign three responses for each question (never, sometimes, and always), adding 
a value to each response (0, 2 and 4, respectively) and reaching a score ranging 
from 0 to 100. Moreover, each patient performs a self-evaluation of their 
dysphagia, assigning a score from 0 (normal) to 7 (severe difficulty) [31] The DHI 
has 9 questions in the functional subscale, 9 question in the physical subscale, 
and 7 questions in the emotional subscale [32] 
 
Randomization (Parallel Design) 
Out of 90 PD patients 33 patients had dysphagia and participated in the study 
(see flow chart figure 1). Group allocations (real or sham with ratio 2:1) were 
placed in serially numbered opaque closed envelopes. Each patient was placed 
in the appropriate group after opening the corresponding sealed envelope. 
Measuring resting motor threshold  
Resting motor threshold was measured with a monophasic magnetic stimulator 
(Magstim model 200; Magstim, Whitland, UK) connected to a 90-mm outer 
diameter figure- of-8 coil, which had a maximal output of 2.2 Tesla. We located 
the optimal scalp location of each hemisphere from which TMS evoked motor-
evoked potentials of greatest amplitude by moving the figure-of-8 coil 
systematically in 1-cm steps to determine the site of maximum peak-to-peak 
motor-evoked potentials in the first dorsal interosseous for each hemisphere. We 
used silver–silver chloride surface electrodes, using a muscle belly-tendon 
montage, with a 3-cm diameter circular ground electrode placed on the wrist. A 
Nihon Kohden Machine model 9400 (Tokyo, Japan) was used to amplify 
and record the signals. 
 
Repetitive Transcranial Magnetic StimulationProcedure 
 
Real rTMS was applied for 10 sessions (5 days per week) using a figure-of-8 coil 
(9-cm diameter loop) positioned over the hand area. A session of stimulation 
consisted of sequential stimulation of each hemisphere (right then left 
hemisphere) with 10 trains of 20-Hz stimulation, each lasting for 10 seconds with 
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an intertrain interval of 25 seconds. The intensity of stimulation was set at 90% of 
the rMT for the first dorsal interosseous of the contralateral hand with a total 2000 
pules for each hemisphere. Given our previous experience in treating PD (Khedr 
et al., 2006) we decided to give 5 booster sessions every month for 3 months 
follow-up. Sham rTMS was applied using the same parameters, but with the coil 
held so that the edge was in contact with the head perpendicular to the scalp while 
the remainder was rotated 90° away from the scalp in the sagittal plane to 
reproduce the noise of the stimulation.  
 
Video-fluoroscopy examination (pre and post 10 sessions).Video-fluoroscopy 
(VFS) was performed before and after rTMS sessions while patients were on 
levodopa therapy using a GE Prestiage II- USA machine. The examination was 
performed in an upright lateral position. The field of examination involved the oral 
cavity and extended down to the upper oesophagus. 5 ml of three different 
consistencies of barium-sulphate (fluid- semisolid- solid) were given to patients 
by a spoon. Cocoa was added to the barium to improve its flavour. Patients were 
requested to hold the barium in their mouth and only start to swallow when asked 
by the clinical investigator. 
Assessment: 
Examinations were recorded and assessment was further performed in slow 
motion in addition to the frame by frame analysis. 
Temporal Measures: 
The pharyngeal transit time (PTT) was measured, in seconds, from the point 
where the bolus head moved from the hold position and passed the posterior 
nasal spine until it fully entered the oesophagus after the closure of the upper 
oesophageal sphincter. The time of the first superior-anterior movement of the 
hyoid bone was assigned as H1, and the time when the hyoid bone reached its 
maximum elevation was assigned as H2. The time required for maximum 
elevation of the hyoid bone was therefore H2- H1. The temporal measures of the 
hyoid bone movement have been previously described [33]. 
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Scoring Measures: 
Penetration (passage of the bolus into the larynx, above the level of the vocal 
cord) and aspiration (passage of the bolus into the larynx, below the level of the 
vocal cord) were assessed using the previously validated 8-point penetration- 
aspiration scale [34]. Finally, post-swallow residue was scored as follows: patients 
with no residue after swallowing were given a score of zero, those who had 
residue either in the vallecular or in the pyriform sinus were given a score of 1, 
while those who had had residue both in the vallecula and pyriform sinus were 
scored 2.  
Follow up 
At the end of the therapy, patients were asked whether they thought they had real 
or sham rTMS. We followed up the patients clinically after the end of the 10th 
session, 1, 2, 3 months later after the end of booster sessions using the 
Dysphagia Handicap Index (DHI) as a primary outcome. The secondary outcome 
measures were changes in video fluoroscopy after the 10th session.  
Assessment of the different scales (A_DHI and UPDRS and other) were 
performed by an assessor who was unaware of the type of stimulation. Likewise, 
the patients also did not know which type of stimulation they received. 
We also asked patients specifically whether they experienced any of the common 
side effects of rTMS. Three patients of the real group refused to complete the 
sessions: one developed headache and insomnia and the other two refuse to stay 
in the hospital.  
 
Ethics: 
Informed consent was obtained from all subjects and the methodology was 
approval by the faculty of medicine ethical committee. 
Statistics: Statistical analysis 
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All data were analyzed with the aid of the SPSS ver.16. The results were 
expressed as mean ± SD. Since some measures were not distributed normally at 
baseline, age, duration of illness and scores on different rating scales in each 
group were compared using the non-parametric Mann-Whitney test. Spearman 
correlations between base line scores were also performed. Statistical analysis of 
the scores in each test was performed with repeated measures analysis of 
variance (ANOVA) with TIME, as the within-subject factor, and treatment 
condition (real, and sham rTMS) as the between subject measure. Greenhouse–
Geisser degree of freedom corrections were applied to correct for the non-
sphericity of the data. P<0.05 was considered significant for all statistical analysis. 
Spearman correlation between the changes in the total UPDRS III (Pre-Post 10th 
sessions) and the changes in DHI (Pre-Post 10th sessions). 
Results: 
Clinical characteristics are summarised in Table 1. There were no significant 
differences between groups in age, sex, duration of illness, and total scores in the 
UPDRS III, IADL, Self-Assessment scale and dysphagia scales. There was a 
significant positive correlation between UPDRS Part III and SDQ and total A-
Dysphagia Handicap Index at baseline with r= 0.77 (P = 0.0001) and r =0.79 (P = 
0.0001) respectively. 
 
Clinical scores (UPDRS III, Self-assessment scale and Instrumental Daily 
living activity) (table 2a) 
One way repeated measures ANOVA (pre, post treatment and one, two and three 
months later) showed a significant effect of time on all rating scales (UPDRS III, 
IADL, self-assessment) in the real group while no such changes were observed 
in the sham group. Two-way repeated measures ANOVAs on the scores for each 
rating scale, with treatment CONDITION (real and sham) and TIME (baseline, 
post treatment, one, two and three months later) as main factors revealed a 
significant interaction effect for UPDRS III and Self-Assessment scores. There 
was no significant interaction for IADL. The mean change in UPDRS III (Pre-Post 
10th session) was significantly higher in the real group (22.0+ 9.9) than in the sham 
group (2.3+ 5.4; P= 0.0001). 
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Dysphagia scores (A-Dysphagia Handicap Index) (table 2b and figure 2). 
One way repeated measures ANOVA (pre, post treatment and one, two and three 
months later) showed a significant effect of time on all sub items (functional, 
physical, and emotional) as well as the total score of the Arabic-Dysphagia 
Handicap index in the real group while no such changes were observed in the 
sham group. Two-way repeated measures ANOVAs on the scores for each rating 
scale, with treatment CONDITION (real and sham) and TIME (baseline, post 
treatment, one, two and three months later) as main factors revealed a significant 
interaction effect for A- DHI sub-items and total scores. The mean reduction in the 
A-DHI (Pre-Post 10th session) was significantly greater (good improvement) in the 
real group (14.4 + 9.9) than the sham group (0.9+ 3.0) (P= 0.0001). There was a 
significant positive correlation between the changes of UPDRS III and the 
changes in DHI Score (r= 0.68 and P= 0.0001). 
 
Video-fluoroscopy (table 3, figure 3a and b) 
Two-way ANOVA showed significant Time (pre, post) X Group (real, sham) 
interaction between groups for solid swallows (P= 0.007, 0.03 respectively), due 
to a significant improvement in the real rTMS group but not sham. There were no 
significant interactions for fluid or semisolid swallows. However, paired t-tests 
showed a significant improvement in H1-H2, and PTT for fluid swallowing in the 
real rTMS group (P= 0.04, and 0.03 respectively) while no such changes were 
observed in the sham group. There was no difference between groups in the 
scores of penetration/aspiration or residue. 
 
 
 
 
Discussion 
The mechanisms of dysphagia in PD are still unclear and this has limited progress 
in the management dysphagia.  Levodopa treatment generally is accepted to have 
little effect on dysphagia in PD [8], and there are even a few (small-sized) studies 
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with formal assessments reporting that levodopa has an unfavorable effect on 
swallowing [5, 35]. Here we explored the possibility of employing new 
neuromodulatory methods to tackle dysphagia in PD. As noted in the Introduction, 
several previous studies have shown that rTMS can have beneficial effects in 
post-stroke dysphagia as well as dysphagia following a lateral medullary 
syndrome [36, 37]. rTMS has also been reported to have beneficial effects on limb 
movement symptoms in PD. Thus a logical progression is to assess the effect of 
rTMS in treating dysphagia in PD. Applying rTMS approaches to different disease 
aetiologies will provide us further information about the endogenous plastic 
changes in humans with regard to swallowing function. 
In the present study we applied bilateral high frequency rTMS to treat dysphagia 
in PD. The rationale was that our previous work had shown that high frequency 
rTMS increases the excitability of M1 in healthy volunteers [38] and improves 
motor performance in patients with PD [39]. This was confirmed by Lomarev et al 
[40] who applied high frequency rTMS bilaterally (4 cortical targets: left and right 
motor and dorsolateral prefrontal cortex) in 18 PD patients and also reported that 
times for executing walking and complex hand movement tests gradually 
decreased [40]. Since we have shown that high frequency rTMS can improve 
post-stroke dysphagia, we chose to use the same parameters in the present 
study, reasoning that if we applied the TMS over motor cortex we would achieve 
a positive effect on movement control as well as dysphagia. Indeed, we found that 
rTMS over the motor hand area improved both dysphagia and motor scores as 
measured by A-DHI rating scores,  UPDRS III, and SA respectively, whereas 
there was no effect of sham. Our results were confirmed by video-fluoroscopy, at 
least for solid swallows. 
 
The rigidity, hypertonia, bradykinesia and involuntary movements in PD can 
interfere in the motor control of swallowing, increasing the risk for penetration and 
laryngeal aspiration. It has been suggested that rigidity and bradykinesia of may 
compromise the oral preparatory phase, which is under volitional motor control. 
These are the symptoms most likely to be ameliorated by rTMS, and it therefore 
would seem logical to have some improvement of swallowing. However, whether 
these are the most important factors in producing the improvement we observed 
is unclear since treatment with levodopa, which has good positive effects on 
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bradykinesia and rigidity is usually reported to have little or even an unfavorable 
effect on swallowing [5, 8, 35]. 
Although we targeted the hand/arm area of motor cortex, its close proximity to 
structures including the esophageal motor area cannot fully exclude the possibility 
that the after-effects we saw were due to excitability changes at esophageal motor 
cortex which might have more direct effects on corticobulbar activity and 
excitability.  
In recent years, neuroimaging and neurostimulation studies have provided 
insights into the activation patterns of the swallowing sequence [41, 42]. A meta-
analysis of imaging studies on swallowing [43] showed that the most consistent 
areas that are activated in these neuroimaging studies include the primary 
sensorimotor cortex (M1/S1), sensorimotor integration areas, the insula and 
frontal operculum, the anterior cingulate cortex and supplementary motor areas. 
In the present study stimulation of M1 could enhance the functional connectivity 
of swallowing network and interactions of involved brain regions as it has been 
described for resting state and during swallowing [44-46]. 
 
 
Videofluoroscopy is an objective measure of swallowing function but was only 
available in about half of the patients, limiting the statistical power. Nevertheless 
we observed a significant difference in the effect of real v sham rTMS on the PTT 
and H1-H2 times for solid swallows. Interestingly, both measure movement speed 
and are related to the bradykinesia and hypokinesia of limb movement [47]. A 
similar result could be seen in fluid swallows but this was not significant, perhaps 
because this is more difficult to quantify in the absence of computerized methods 
of assessment. However despite this improvement in speed of transit of the food 
bolus through the pharyngeal cavity there was no difference in the P/A or residue 
scores. The pharyngeal residue reflects impairment of pharyngeal muscle 
contractility and the subsequent weak propulsion of the bolus [48]. The small size 
of the bolus used in our study might have contributed to the lack of the difference 
in the residue scores. The mild degree of penetration reported in our population, 
might explain the lack of effect on P/A scores. 
 
Limitations 
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 Small sample size limits the power of this study and a larger sample size is 
recommended for future investigations.  In addition, obtaining an adequate sham 
for rTMS is tricky. However, given that our participants had not received any TMS 
previously we do not think they would have perceived they were being given sham 
treatment. A possible solution in future trials might be to consider active 
stimulation at an inactive scalp site as we have done in previous study [39]. 
Another limitation was the absence of a healthy control arm for videofloroscopy. 
 
Conclusions 
The main conclusion is that real rTMS improves dysphagia in Parkinson’s disease 
as documented by A-DHI scores and by video-fluoroscopy. The effect can be 
seen immediately following the last treatment session and up to 3 months later. 
However, it should be noted that over that three month follow-up period, patients 
were receiving a “top-up” treatment of 5 rTMS sessions every month, and this 
may have been instrumental in maintaining the effect. 
 
 
 
 
 
 
 
References: 
 
1. Khedr EM, Al Attar GS, Kandil MR, Kamel NF, Elfetoh NA, et al. (2012) 
Epidemiological study and clinical profile of parkinson’s disease in the assiut 
governorate, egypt: A community-based study. Neuroepidemiology. 38(3): 
154-163. 
2. Eadie MTyrer J (1965) Alimentary disorder in parkinsonism. Australasian 
annals of medicine. 14(1): 13-22. 
3. Edwards LL, Quigley EMPfeiffer RF (1992) Gastrointestinal dysfunction in 
parkinson's disease: Frequency and pathophysiology. Neurology. 42(4): 726-
32. 
13 
 
4. Stroudley JWalsh M (1991) Radiological assessment of dysphagia in 
parkinson's disease. The British Journal of Radiology. 64(766): 890-893. 
5. Hunter PC, Crameri J, Austin S, Woodward MCHughes AJ (1997) Response 
of parkinsonian swallowing dysfunction to dopaminergic stimulation. J Neurol 
Neurosurg Psychiatry. 63(5): 579-83. 
6. Logemann JA (1998) The evaluation and treatment of swallowing disorders. 
Current Opinion in Otolaryngology & Head and Neck Surgery. 6(6): 395-400. 
7. Calne DB, Shaw DG, Spiers ASDStern GM (1970) Swallowing in 
parkinsonism. The British Journal of Radiology. 43(511): 456-457. 
8. Menezes CMelo A (2009) Does levodopa improve swallowing dysfunction in 
parkinson’s disease patients? Journal of Clinical Pharmacy and Therapeutics. 
34(6): 673-676. 
9. Bushmann M, Dobmeyer SM, Leeker LPerlmutter JS (1989) Swallowing 
abnormalities and their response to treatment in parkinson's disease. 
Neurology. 39(10): 1309-14. 
10. Robbins J, Gensler G, Hind J, Logemann JA, Lindblad AS, et al. (2008) 
Comparison of 2 interventions for liquid aspiration on pneumonia incidence: 
A randomized trial. Ann Intern Med. 148(7): 509-18. 
11. Jost WH (2010) Gastrointestinal dysfunction in parkinson's disease. Journal 
of the Neurological Sciences. 289(1-2): 69-73. 
12. Troche MS, Okun MS, Rosenbek JC, Musson N, Fernandez HH, et al. (2010) 
Aspiration and swallowing in parkinson disease and rehabilitation with emst: 
A randomized trial. Neurology. 75(21): 1912-1919. 
13. Manor Y, Mootanah R, Freud D, Giladi NCohen JT (2013) Video-assisted 
swallowing therapy for patients with parkinson's disease. Parkinsonism & 
Related Disorders. 19(2): 207-211. 
14. Born LJ, Harned RH, Rikkers LF, Pfeiffer RFQuigley EMM (1996) 
Cricopharyngeal dysfunction in parkinson's disease: Role in dysphagia and 
response to myotomy. Movement disorders. 11(1): 53-58. 
15. Restivo DA, Palmeri AMarchese-Ragona R (2002) Botulinum toxin for 
cricopharyngeal dysfunction in parkinson's disease. New England Journal of 
Medicine. 346(15): 1174-1175. 
16. Baijens LW, Speyer R, Passos VL, Pilz W, Van Der Kruis J, et al. (2013) 
Surface electrical stimulation in dysphagic parkinson patients: A randomized 
clinical trial. The Laryngoscope. 123(11): E38-E44. 
17. Hamdy S, Jilani S, Price V, Parker C, Hall N, et al. (2003) Modulation of 
human swallowing behaviour by thermal and chemical stimulation in health 
and after brain injury. Neurogastroenterology & Motility. 15(1): 69-77. 
18. Hamdy S, Rothwell JC, Aziz QThompson DG (2000) Organization and 
reorganization of human swallowing motor cortex: Implications for recovery 
after stroke. Clinical science. 99(2): 151-157. 
19. Khedr EM, Abo-Elfetoh N, Ahmed MA, Kamel NF, Farook M, et al. (2008) 
Dysphagia and hemispheric stroke: A transcranial magnetic study. 
Neurophysiologie Clinique/Clinical Neurophysiology. 38(4): 235-242. 
14 
 
20. Liao X, Xing G, Guo Z, Jin Y, Tang Q, et al. (2017) Repetitive transcranial 
magnetic stimulation as an alternative therapy for dysphagia after stroke: A 
systematic review and meta-analysis. Clinical Rehabilitation. 31(3): 289-298. 
21. Siebner HR, Mentschel C, Auer CConrad B (1999) Repetitive transcranial 
magnetic stimulation has a beneficial effect on bradykinesia in parkinson's 
disease. Neuroreport. 10(3): 589-594. 
22. Hughes A, Ben-Shlomo Y, Daniel SLees A (1992) Uk parkinson's disease 
society brain bank clinical diagnostic criteria. J Neurol Neurosurg Psychiatr. 
55(181): e4. 
23. Kurlowicz LWallace M (1999) The mini-mental state examination (mmse). 
Journal of gerontological nursing. 25(5): 8-9. 
24. Sharp R (2015) The hamilton rating scale for depression. Occupational 
Medicine. 65(4): 340-340. 
25. Zhao YJ, Wee HL, Chan YH, Seah SH, Au WL, et al. (2010) Progression of 
parkinson's disease as evaluated by hoehn and yahr stage transition times. 
Movement disorders. 25(6): 710-716. 
26. Fahn S (1987) Unified parkinson's disease rating scale. Recent development 
in Parkinson's disease. 
27. Lawton MBrody E (1969) Instrumental activities of daily living scale (iadl). The 
Gerontologist. 9: 179-186. 
28. Brown RG, Maccarthy B, Jahanshahi MMarsden CD (1989) Accuracy of self-
reported disability in patients with parkinsonism. Archives of Neurology. 46(9): 
955-959. 
29. Cohen JTManor Y (2011) Swallowing disturbance questionnaire for detecting 
dysphagia. The Laryngoscope. 121(7): 1383-1387. 
30. Farahat M, Malki KH, Mesallam TA, Bukhari MAlharethy S (2014) 
Development of the arabic version of dysphagia handicap index (dhi). 
Dysphagia. 29(4): 459-467. 
31. Silbergleit AK, Schultz L, Jacobson BH, Beardsley TJohnson AF (2012) The 
dysphagia handicap index: Development and validation. Dysphagia. 27(1): 
46-52. 
32. Sallum RaA, Duarte AFCecconello I (2012) Analytic review of dysphagia 
scales. ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo). 25(4): 
279-282. 
33. Kendall KA, Mckenzie S, Leonard RJ, Gonçalves MIWalker A (2014) Timing 
of events in normal swallowing: A videofluoroscopic study. Dysphagia. 15(2): 
74-83. 
34. Rosenbek JC, Robbins JA, Roecker EB, Coyle JLWood JL (1996) A 
penetration-aspiration scale. Dysphagia. 11(2): 93-8. 
35. Monte FS, Da Silva-Júnior FP, Braga-Neto P, Nobre E Souza MÂSales De 
Bruin VM (2005) Swallowing abnormalities and dyskinesia in parkinson's 
disease. Movement disorders. 20(4): 457-462. 
15 
 
36. Khedr EMAbo-Elfetoh N (2010) Therapeutic role of rtms on recovery of 
dysphagia in patients with lateral medullary syndrome and brainstem 
infarction. Journal of Neurology, Neurosurgery & Psychiatry. 81(5): 495-499. 
37. Khedr EM, Abo-Elfetoh NRothwell JC (2009) Treatment of post-stroke 
dysphagia with repetitive transcranial magnetic stimulation. Acta Neurologica 
Scandinavica. 119(3): 155-161. 
38. Khedr EM, Rothwell JC, Ahmed MA, Shawky OAFarouk M (2007) Modulation 
of motor cortical excitability following rapid-rate transcranial magnetic 
stimulation. Clinical neurophysiology. 118(1): 140-145. 
39. Khedr EM, Rothwell JC, Shawky OA, Ahmed MAHamdy A (2006) Effect of 
daily repetitive transcranial magnetic stimulation on motor performance in 
parkinson's disease. Mov Disord. 21(12): 2201-5. 
40. Lomarev MP, Kanchana S, Bara-Jimenez W, Iyer M, Wassermann EM, et al. 
(2006) Placebo-controlled study of rtms for the treatment of parkinson's 
disease. Movement disorders. 21(3): 325-331. 
41. Martin RE (2009) Neuroplasticity and swallowing. Dysphagia. 24(2): 218-229. 
42. Michou EHamdy S (2009) Cortical input in control of swallowing. Current 
Opinion in Otolaryngology & Head and Neck Surgery. 17(3): 166-171. 
43. Sörös P, Inamoto YMartin RE (2009) Functional brain imaging of swallowing: 
An activation likelihood estimation meta-analysis. Human Brain Mapping. 
30(8): 2426-2439. 
44. Babaei A, Siwiec RM, Kern M, Douglas Ward B, Li SJ, et al. (2013) Intrinsic 
functional connectivity of the brain swallowing network during subliminal 
esophageal acid stimulation. Neurogastroenterology & Motility. 25(12): 992-
e779. 
45. Babaei A, Ward BD, Siwiec RM, Ahmad S, Kern M, et al. (2013) Functional 
connectivity of the cortical swallowing network in humans. NeuroImage. 76: 
33-44. 
46. Lowell SY, Reynolds RC, Chen G, Horwitz BLudlow CL (2012) Functional 
connectivity and laterality of the motor and sensory components in the 
volitional swallowing network. Experimental Brain Research. 219(1): 85-96. 
47. Ciucci MR, Barkmeier-Kraemer JMSherman SJ (2008) Subthalamic nucleus 
deep brain stimulation improves deglutition in parkinson's disease. Movement 
disorders. 23(5): 676-683. 
48. Rommel N, Borgers C, Van Beckevoort D, Goeleven A, Dejaeger E, et al. 
(2015) Bolus residue scale: An easy-to-use and reliable videofluoroscopic 
analysis tool to score bolus residue in patients with dysphagia. International 
journal of otolaryngology. 2015. 
 
 
 
 
16 
 
 
 
 
 
 
  
17 
 
 
Table 1: Demographic, clinical and staging data at baseline assessment  
 
 
Variable Real rTMS Group (19 
patients. Mean ± SD 
Sham rTMS Group (11 
patients). Mean ± SD 
P value 
Mann-
Whitney 
test 
Patients Age (years) 60.7 ± 8.8 57.4 ± 10.0 0.16 
Age at Onset (years) 55.1 ± 10.4 53.9 ± 10.7 0.18 
Duration of Illness (years) 5.7 ± 3.9 6.5 ± 3.7 0.36 
Total Score of UPDRS III 61.9 ± 13.2 64.6 ± 19.9  0.84 
Hoehn and Yahr 3.1 ± 1.1 3.5 ± 1.0 0.18 
 IADL 16.4 ± 4.5  15.5 ± 5.0  0.34 
self-assessment 18.7 ± 2.4   18.3 ± 3.4   0.74 
Total score of Arabic Dysphagia Handicap 
Index 
 36.0 ± 14.9 33.4 ± 15.0 0.63 
Swallowing disturbance questionnaire   17.4 ± 6.1 16.2 ± 5.8 0.50 
 
UPDRS III; Unified Parkinson’s Disease Rating Scale part III; IADL; Instrumental 
activity of Daily Living  
 
 
 
 
 
Table 2a: Effect of 10 sessions of high frequency rTMS on different clinical rating 
scales (UPDRS  III, IDAL and self-Assessment) among studied groups 
 
 
UPDRS III; Unified Parkinson’s Disease Rating Scale part III; IADL; Instrumental 
activity of Daily Living  
 
 
P value Two Way 
ANOVA Time X Group 
Post 3month Post 2 month Post 1 month Post 10 sessions Pre-sessions  
 (UPDR III) 
P= 0.0001, df= 2.18(59), 
F= 20.3 
45.8 ± 13.1  
64.2 ± 18.2 
45.4 ± 13.4 
62.9 ± 18.3 
43.7 ± 14.4 
62.3 ± 18.8 
39.7 ± 14.5 
61.0 ± 17.5  
61.9 ± 13.2 
64.6 ± 19.9 
Real 
Sham 
      Hoehn and Yahr 
P= 0.21, df= 1.0(27), 
F=1.6 
2.8 ± 0.98 
3.6 ± 0.97 
2.8 ± 0.96 
3.6 ± 0.97 
2.7 ± 0.80 
3.5 ± 0.97 
2.6 ± 0.79 
3.5 ± 0.97 
3.1 ± 1.1 
3.5 ± 1.0 
Real 
Sham 
      (IDAL) 
P= 0.066, df= 1.4(38), 
F=3.2 
18.9 ± 4.9 
15.2 ± 4.6 
18.5 ± 5.3 
15.1 ± 4.7 
18.6 ± 5.2 
15.0 ± 4.8 
19.3 ± 5.5 
15.5 ± 4.8 
16.4 ± 4.5  
15.0 ± 5.0 
Real  
Sham 
 Self-Assessment scale 
P= 0.0001, df= 2.9 (76), 
F= 17.9 
14.5 ± 2.5  
18.0 ± 3.3  
14.3 ± 2.5  
18.2 ± 3.1 
14.0 ± 2.0 
18.4 ± 3,6 
13.6 ± 2.4 
17.9 ± 3.2 
18.7 ± 2.4  
18.8 ± 3.6  
Real  
Sham  
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Table 2b: Effect of 10 sessions of high frequency rTMS on A – Dysphagia 
Handicap Index among studied groups 
 
 
P value Two Way ANOVA 
Time X Group 
Post 3 
months 
Post 2 
months 
Post 1 
month 
Post 10 
sessions 
Pre-
sessions 
 
A – Dysphagia Handicap Index (functional)  
P= 0.0001, df= 2.4 (63), F= 
10.7 
9.9* ± 5.2  
15.1 ± 6.8 
9.8* ± 5.0  
15.6 ± 7.1 
9.4* ± 4.3 
14.0 ± 6.4 
8.9** ± 4.1  
14.7 ± 6.9  
14.5 ± 5.5 
14.6 ± 6.8  
Real  
Sham  
A – Dysphagia Handicap Index (DHI physical)  
P= 0.0001, df= 1.6 (42), F= 
16.7 
9.2* ± 6.2 
14.6 ± 7.2 
9.2* ± 6.2 
14.4 ± 7.3 
8.7* ± 6.2 
14.4 ± 6.8 
8.8* ± 5.7 
14.0 ± 7.1  
15.7 ± 7.0 
14.6 ± 7.4  
Real 
Sham  
A – Dysphagia Handicap Index (emotional)  
P= 0.02, df= 1.6 (32), F= 5.5 3.4 ± 2.7 
4.7 ± 2.2 
3.4 ± 2.7 
4.7 ± 2.2 
3.5 ± 2.7 
4.7 ± 2.2 
3.7 ± 2.8 
4.2 ± 2.4  
5.8 ± 4.0   
4.9 ± 2.1  
Real  
Sham 
A – Dysphagia Handicap Index (total)  
P= 0.0001, df= 1.5 (38), F= 
15.6 
22.6* ± 12.4  
34.4± 15.1 
22.3*± 12.4  
34.4 ± 14.7 
21.6*±11.6 
32.9 ± 14.1 
21.5*± 10.9 
32.6 ± 15.0 
36.0 ± 15.0 
33.5 ± 15.1  
Real  
Sham 
A – Dysphagia Handicap Index ( impression)  
P= 0.0001, df= 1.4 (36), F= 
14.6 
3.1 ± 1.1 
4.0 ± 1.9  
3.0 ± 1.0  
3.9 ± 1.8  
3.1 ± 1.1 
3.7 ± 1.7 
2.8 ± 1.0 
3.8 ± 1.7  
5.0 ± 1.2  
4.2 ± 1.7  
Real  
Sham  
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Table 3: Videofluroscopy details of each items Pre and post sessions in studied 
groups 
 
 PTT; The pharyngeal transit time; H1; the time of the first superior-anterior movement of the hyoid 
bone, H2 the time when the hyoid bone reaches the maximum elevation, PA score; penetration- 
aspiration scale, Residue; post-swallow residueH2-H1 
 
 
Pre 
session 
(H2-H1) 
post 
session
s (H2-
H1) 
P value 
Paired t-
test 
Pre 
session 
PTT 
Post- 
session 
PTT 
P value 
Paired t-
test 
Pre 
session 
PAscor
e 
Post 
session 
PAscor
e 
P 
value 
Paired 
t-test 
Pre 
session 
residue 
Post 
session 
residue 
P value 
Paired t-
test 
FLUID 
Real group (9 cases) 
Sham group (6 cases) 
 
1.0±0.7 
0.8±0.7 
 
0.6±0.3 
0.8± 0.6 
 
P=0.04 
P = 0.9 
 
1.6±0.7 
1.4± 0.9 
 
1.1±0.3 
1.2±0.7 
 
P=0.03 
P= 0.3 
 
 
 
1.9±0.8  
 
1.5±0.5 
 
 
 
1.4±0.7  
 
1.3±0.5 
 
 
P=0.1 
P= 0.3 
 
0.9±0.6 
1.2±0.7 
 
0.7±0.7 
1.2±0.7` 
 
P=0.16 
P= 0.9 
Two ways ANOVA 
Time X Groups 
Df=1(13), F= 0.3, P= 0.10 Df=1(13), F= 1.5, P= 0.2 Df=1(13), F= 0.7, P= 0.4 Df=1(13), F= 1.5, P= 0.2 
SEMISOLID 
Real group (9 cases) 
Sham group(6 cases) 
 
1.1±0.9 
1.1±0.9 
 
0.6±0.3 
0.9± 0.6 
 
P=0.2 
P = 0.3 
 
1.5±0.8 
1.6± 0.7 
 
1.2±0.6 
1.4±0.7 
 
P=0.3 
P= 0.2 
 
 
 
1.4±0.7 
 
1.3±0.5 
 
 
 
1.2±0.7  
 
1.2±0.5 
 
 
P=0.2 
P= 0.4 
 
0.9±0.6 
1.3±0.8 
 
0.7±0.7 
1.2±0.4` 
 
P=0.16 
P= 0.9 
two ways ANOVA 
(Time X Group) 
Df=1(13) F=0.4, P = 0.5 Df=1(13) F=0.01, P = 0.93 Df=1(13), F=0.6, P = 0.8 Df=1(13), F=0.03, P = 0.8 
SOLID 
Real group (9 cases) 
Sham group(6 cases) 
 
0.7±0.6 
0.8±0.7 
 
0.5±0.4 
0.9± 0.7 
 
P=0.009 
P = 0.19 
 
1.4±0.6 
1.4± 0.7 
 
1.1±0.5 
1.5±0.7 
 
P=0.01 
P= 0.6 
 
 
 
1.4±0.7  
 
1.2±0.4 
 
 
 
1.2±0.7  
 
1.1±0.0 
 
 
P=0.4 
P= 0.4 
 
1.1±0.6 
1.3±0.8 
 
0.9±0.6 
1.3±0.5 
 
P=0.16 
P= 1.0 
Two ways ANOVA 
Time X Groups 
Df=1(13), F=10.3,  P = 0.007 Df=1(13), F=5.3, P = 0.03 Df=1(13), F=0.8,  P = 0.7 Df=1(13), F=0.65, P = 0.4 
20 
 
 
 
Figure 1 flow chart 
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Figure 2: Show changes in Arabic Dysphagia Handicap Index among the studied 
group. A significant effect of time (pre, post treatment and one, two and three 
months later) on all sub items (functional, physical, and emotional) as well as the 
total score of the Arabic-Dysphagia Handicap index in the real group while no 
such changes were observed in the sham group. A significant interaction effect 
(time Xgroup) for A- DHI subitems and total scores 
 
 
 
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3a: Lateral fluoroscopic views in a PD patient with dysphagia. A) Before 
rTMS sessions, there is a penetration, scored as (3) on the penetration-aspiration 
scale, with fluid bolus entering the airway (arrow). B) Notable improvement is 
shown after rTMS sessions, with no evidence of penetration. Sore (1) on the 
penetration-aspiration scale. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3b: Lateral fluoroscopic views in a PD patient with dysphagia. A) Before 
rTMS sessions, residual barium is filling the vallecula (arrow). B) No notable 
clearance of the barium after rTMS 
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